Endometrial hyperplasia and endometrioid adenocarcinoma of the endometrium Cancer
Conditions
Interventions
Current intervention as of 11/04/2023:
A detailed gynaecological history, including parity, menstrual abnormalities, hormonal and contraceptive use will be taken when recruited. Weight
Sponsors
Central Manchester University Hospitals NHS Trust (CMFT) (UK)
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Age 18 or more 2. Attending the gynaecological outpatient clinic at St Mary?s Hospital 3. Biopsy-proven well differentiated endometrioid adenocarcinoma of the endometrium (EC) with no myometrial invasion and/or endometrial hyperplasia (EH) 4. Clinical decision to treat EH or EC with progestins 5. Written, informed consent to take part in the study; Target Gender: Female
Exclusion criteria
Exclusion criteria: 1. Non endometrioid or mixed histology or concerning histological features 2. Myometrial invasion on imaging 3. Progestin therapy contraindicated 4. Unable to sample endometrium pre/post progestin therapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Current primary outcome measure as of 11/04/2023: Ki-67 and progesterone receptor status; Timepoint(s): At approximately 3-monthly intervals (for up to a total of 60 months) _____ Previous primary outcome measure: Ki-67 and progesterone receptor status; Timepoint(s): At approximately 3 monthly intervals (for up to a total of 12 months) | — |
Secondary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Countries
England, United Kingdom
Outcome results
None listed